Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18430368 | 0.83 | KDM4E (0.36) | KDM4EPOLBALOX15EPHX2LMNA | |
| SCHEMBL16843122 | 0.82 | KDM4E (0.40) | KDM4EPOLBALOX15EPHX2LMNA | |
| SCHEMBL25493068 | 0.82 | KDM4E (0.39) | KDM4EPOLBALOX15EPHX2LMNA | |
| SCHEMBL1087617 | 0.80 | EPHX2 (0.41) | KDM4EPOLBALOX15EPHX2LMNA | |
| SCHEMBL10582523 | 0.79 | KDM4E (0.45) | KDM4EPOLBALOX15LMNAALDH1A1 | |
| SCHEMBL6537290 | 0.78 | KDM4E (0.39) | KDM4EPOLBALOX15EPHX2LMNA | |
| SCHEMBL21827100 | 0.78 | KDM4E (0.38) | KDM4EPOLBALOX15ALDH1A1MAPT | |
| SCHEMBL5349663 | 0.78 | KDM4E (0.39) | KDM4EPOLBALOX15EPHX2LMNA | |
| SCHEMBL4104590 | 0.78 | ALDH1A1 (0.40) | KDM4EPOLBALOX15EPHX2LMNA | |
| SCHEMBL32688759 | 0.78 | ALDH1A1 (0.40) | KDM4EPOLBALOX15EPHX2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078079-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NORBORNANE AND NORBORNENE DERIVATIVES | OSMO LABS PBC (US) | 2026-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078079-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NORBORNANE AND NORBORNENE DERIVATIVES | CBR1, CBR3, TAS2R1 | KDM4E 4643/4885POLB 1910/4885ALOX15 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.